Form 4: Revolution Medicines Director Flavia Borellini Reports Acquisition of Shares and Stock Options

Director Flavia Borellini reports acquisition of 4,800 shares of common stock and 16,700 stock options in Revolution Medicines, Inc.

Summary

• On June 20, 2024, Flavia Borellini, a director of Revolution Medicines, Inc., acquired 4,800 shares of common stock at $0.
• Following this transaction, Borellini directly owns 22,434 shares of common stock, which includes 5,403 Restricted Stock Units.
• Borellini also acquired 16,700 stock options with an exercise price of $37.54.
• These options vest on the earlier of June 20, 2025, or immediately before the Annual Meeting following the grant date, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. Insider buying is generally viewed positively, but this is a routine disclosure.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the stock options is contingent on the Reporting Person remaining a Service Provider through the vesting date, suggesting continued involvement with the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• The acquisition of shares and stock options by a director may positively influence shareholder confidence.

Key Dates